Alfonso Savastano, MD, PhD spoke about the SING-IMT implant during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September ...

The retina space continues to see new advancements and clinical trial results, many of which are shared at industry conferences throughout the year. The medical community, and especially the ...

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Chinese researchers reported finding β-amyloid (Aβ) deposits along the ocular glymphatic system in patients with Alzheimer's disease (AD) and in a 5×FAD transgenic mouse model, 1 according to Dr.

Enrico Borrelli, MD, FEBO, speaks about opportunities in the retina space At this year's EURETINA Congress, we caught up with Enrico Borrelli, MD, FEBO, during a break from his busy schedule. He is ...

It is not every day that a paper about treating eye disease appears in The Lancet. 1 The article by Campochiaro et al1 on a clinical trial of gene therapy speaks to the potential impact of this ...

Carl Awh, MD, FASRS, spoke about the presence of members of the American Society of Retina Specialists (ASRS) attending the EURETINA meeting and the value of the international community of retina ...

TIME Magazine named Zack Dvey-Aharon, PhD, to the 2024 TIME100 AI list. This annual list highlights the 100 most influential individuals in artificial intelligence (AI). According to a press release 1 ...

A recent study reported that proven early-onset sepsis is an early risk factor for severe retinopathy of prematurity (ROP), 1 according to first author Salma El Emrani, BSc, who is from the Department ...

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1. Priovant Therapeutics has enrolled the first patients in the CLARITY Phase 3 study evaluating brepocitinib in ...

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab At this year's EURETINA Congress, Timothy L Jackson PhD, MB ChB ...